Your browser doesn't support javascript.
loading
A strategy to assess the cellular activity of E3 ligase components against neo-substrates using electrophilic probes.
Pinch, Benika J; Buckley, Dennis L; Gleim, Scott; Brittain, Scott M; Tandeske, Laura; D'Alessandro, Pier Luca; Hauseman, Zachary J; Lipps, Jennifer; Xu, Lei; Harvey, Edward P; Schirle, Markus; Sprague, Elizabeth R; Forrester, William C; Dovala, Dustin; McGregor, Lynn M; Thoma, Claudio R.
Afiliação
  • Pinch BJ; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: benika.pinch@novartis.com.
  • Buckley DL; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Gleim S; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Brittain SM; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Tandeske L; Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA.
  • D'Alessandro PL; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Hauseman ZJ; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Lipps J; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Xu L; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Harvey EP; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Schirle M; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Sprague ER; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Forrester WC; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: william.forrester@novartis.com.
  • Dovala D; Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA. Electronic address: dustin.dovala@novartis.com.
  • McGregor LM; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: lynn.mcgregor@novartis.com.
  • Thoma CR; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. Electronic address: claudio.thoma@novartis.com.
Cell Chem Biol ; 29(1): 57-66.e6, 2022 01 20.
Article em En | MEDLINE | ID: mdl-34499862
ABSTRACT
While there are hundreds of predicted E3 ligases, characterizing their applications for targeted protein degradation has proved challenging. Here, we report a chemical biology approach to evaluate the ability of modified recombinant E3 ligase components to support neo-substrate degradation. Bypassing the need for specific E3 ligase binders, we use maleimide-thiol chemistry for covalent functionalization followed by E3 electroporation (COFFEE) in live cells. We demonstrate that electroporated recombinant von Hippel-Lindau (VHL) protein, covalently functionalized at its ligandable cysteine with JQ1 or dasatinib, induces degradation of BRD4 or tyrosine kinases, respectively. Furthermore, by applying COFFEE to SPSB2, a Cullin-RING ligase 5 receptor, as well as to SKP1, the adaptor protein for Cullin-RING ligase 1 F box (SCF) complexes, we validate this method as a powerful approach to define the activity of previously uncharacterized ubiquitin ligase components, and provide further evidence that not only E3 ligase receptors but also adaptors can be directly hijacked for neo-substrate degradation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article